Welcome to our dedicated page for ZEAL news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on ZEAL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZEAL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZEAL's position in the market.
Zealand Pharma (NASDAQ: ZEAL) reported its total number of shares and voting rights as of December 30, 2021, following the recent exercise of employee warrants. The company now has a total of 43,643,142 shares and 43,643,142 voting rights, reflecting its current share capital. This announcement complies with the Danish Capital Markets Act requirements. Zealand Pharma, focused on peptide-based medicines, has progressed more than 10 drug candidates into clinical development.
Zealand Pharma (NASDAQ: ZEAL) announced that The Capital Group Companies now holds 5.61% of its voting rights. This notification, in compliance with the Danish Capital Markets Act, specifies that the SMALLCAP World Fund also holds 5.61% of share capital. Zealand, based in Copenhagen, focuses on peptide-based medicines with products like V-Go® and Zegalogue®. The company aims to enhance patient care through its drug candidates, with several in clinical development.
Zealand Pharma announced the enrollment of the last patient for the interim analysis of its Phase 3 trial (EASE-SBS 1) evaluating glepaglutide for treating short bowel syndrome (SBS). The interim analysis is expected in Q3 2022, with recommendations from an independent Data Monitoring Committee based on unblinded data. Positive interim results could lead to a regulatory submission. The trial aims to reduce parenteral support needs for up to 129 patients over six months. Glepaglutide is designed for subcutaneous administration and has received orphan drug designation from the FDA.
Zealand Pharma announced a significant seven-year financing agreement with Oberland Capital, totaling $200 million. This includes a $100 million upfront payment for a secured, interest-only note. The funding will support the ongoing development of Zealand's clinical pipeline, particularly for dasiglucagon and glepaglutide, targeting metabolic and gastrointestinal diseases. Additional financing options of $50 million are contingent upon the FDA approval of glepaglutide for treating short bowel syndrome. The interest rate is set at 6.0% plus LIBOR.
Zealand Pharma has announced a capital increase of DKK 5,400 by issuing 5,400 new shares, following the exercise of employee warrants. The exercise price was set at DKK 100.8 per share, yielding total proceeds of DKK 544,320. The company’s share capital now stands at DKK 43,634,142, consisting of 43,634,142 shares. These new shares will provide dividend and voting rights, effective immediately upon exercise.
More information about Zealand's warrant programs is available on its website.
Zealand Pharma (NASDAQ: ZEAL) announced on November 30, 2021, a notification from The Capital Group Companies regarding its shareholding status. The company now holds 5.62% of Zealand's voting rights.
The SMALLCAP World Fund, Inc., managed by Capital Group, reported the same percentage of share capital. Zealand focuses on the development of innovative peptide-based medicines, with over 10 drug candidates in clinical development and two already on the market.
Zealand Pharma announced the total number of shares and voting rights as of November 30, 2021. Following an increase in share capital due to employee warrant exercises, the total shares stood at 43,628,742, reflecting an equal number of voting rights. The company remains focused on innovative peptide-based medicines, with more than 10 drug candidates in clinical development, including two already on the market. Zealand Pharma has strategic collaborations with major firms like Boehringer Ingelheim and AstraZeneca.
Zealand Pharma has announced that Credit Suisse Group AG now controls over 5% of Zealand's voting rights and total share capital. This acquisition aligns with Zealand's strategic focus on the development of innovative peptide-based medicines, including products like V-Go and Zegalogue. Zealand's growth trajectory includes more than 10 drug candidates advancing into clinical stages, with two already on the market. This announcement marks significant shareholder engagement and interest in Zealand's ongoing development in the biotechnology sector.
Zealand Pharma has announced the successful outcome of its Phase 1b clinical trial for dapiglutide, a dual receptor agonist targeting GLP1 and GLP2. The trial, involving multiple ascending doses, confirmed dapiglutide's safety and tolerability over four weeks in healthy subjects. Notably, the treatment achieved clinically relevant exposure and demonstrated a linear pharmacokinetic profile with a half-life of approximately 120 hours. Zealand aims to explore various indications for dapiglutide, including gastrointestinal and metabolic diseases.
Zealand Pharma has increased its share capital by DKK 47,045 through the exercise of employee warrants, resulting in 47,045 new shares being issued. The exercise prices varied, with DKK 135.30 for 1,934 shares, DKK 100.80 for 5,111 shares, and DKK 90.00 for 40,000 shares, totaling proceeds of DKK 4,376,859. Following this capital increase, Zealand Pharma’s share capital now stands at DKK 43,628,742. These new shares will be listed on Nasdaq Copenhagen, and each new share carries voting rights and the right to dividends.
